NeoPharm CO. LTD Cash Flow Quality Index
NeoPharm CO. LTD cash flow quality index. NeoPharm CO. LTD (092730) has a Cash Flow Quality Index of 0.86x as of September 2025. Operating cash flow of ₩5.88 Billion is below net income of ₩6.86 Billion, suggesting accrual-heavy earnings not yet converted to cash. See how financially flexible is NeoPharm CO. LTD to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of NeoPharm CO. LTD (2012–2024)
Cash flow quality index of NeoPharm CO. LTD from 2012 to 2024. Historical Cash Flow Quality Index for NeoPharm CO. LTD across 11 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore NeoPharm CO. LTD cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
NeoPharm CO. LTD Cash Flow Quality Index by Year (2012–2024)
NeoPharm CO. LTD cash flow quality index by year from 2012 to 2024. Year-by-year earnings quality comparison for NeoPharm CO. LTD. For the full cash flow conversion analysis, see 092730 cash generation efficiency.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 0.81x | ₩18.63 Billion | ₩23.06 Billion | ▼ -19.4% |
| 2023 | 1.00x | ₩23.26 Billion | ₩23.21 Billion | ▼ -6.0% |
| 2022 | 1.07x | ₩18.16 Billion | ₩17.03 Billion | ▼ -12.9% |
| 2021 | 1.22x | ₩21.68 Billion | ₩17.71 Billion | ▲ +30.0% |
| 2020 | 0.94x | ₩17.07 Billion | ₩18.13 Billion | ▼ -5.7% |
| 2019 | 1.00x | ₩19.22 Billion | ₩19.25 Billion | ▼ -5.1% |
| 2018 | 1.05x | ₩16.18 Billion | ₩15.37 Billion | ▲ +14.3% |
| 2017 | 0.92x | ₩10.65 Billion | ₩11.56 Billion | ▼ -22.1% |
| 2016 | 1.18x | ₩9.16 Billion | ₩7.74 Billion | ▼ -33.9% |
| 2015 | 1.79x | ₩6.09 Billion | ₩3.41 Billion | ▲ +105.3% |
| 2012 | 0.87x | ₩564.34 Million | ₩647.76 Million | — |